Press release
September 3, 2026
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics, Inc. (LTGO)
Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 The New England Journal of Medicine published positive